← Back to Clinical Trials
Recruiting NCT07043153

NCT07043153 AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07043153
Status Recruiting
Phase
Sponsor Sohag University
Condition Systemic Lupus Erythematosus Disease
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2025-08-05
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Albumin to globulin ratio and prognostic nutritional index model

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2025-08-05 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the clinical utility of combining the albumin to globulin ratio (AGR) and the prognostic nutritional index (PNI) as a predictive model for assessing disease activity in patients with systemic lupus erythematosus (SLE). By correlating these nutritional and inflammatory markers with clinical manifestations and laboratory parameters, we hope to establish a simple, non-invasive, and cost-effective tool to aid in monitoring disease activity in Systemic lupus erythematosus patients.

Eligibility Criteria

Inclusion Criteria: * · Age ≥ 18 years. * Both sexes. * Patients diagnosed with SLE who fulfilling the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria and matched controls. Exclusion Criteria: * Co-existing chronic inflammatory or autoimmune diseases. * Age \<18 years * Malignancy. * Pregnancy or lactation. * Chronic liver or renal insufficiency. * Malignant hematologic diseases. * Active hepatitis. * Acute infection within the previous four weeks

Contact & Investigator

Central Contact

Hala A Hamid, Master

✉ Hala.hamed@med.sohag.edu.eg

📞 20 01122385665

Principal Investigator

Esam M Abualfadl, Professor

STUDY CHAIR

Sohag University

Frequently Asked Questions

Who can join the NCT07043153 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Systemic Lupus Erythematosus Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07043153 currently recruiting?

Yes, NCT07043153 is actively recruiting participants. Contact the research team at Hala.hamed@med.sohag.edu.eg for enrollment information.

Where is the NCT07043153 trial being conducted?

This trial is being conducted at Sohag, Egypt.

Who is sponsoring the NCT07043153 clinical trial?

NCT07043153 is sponsored by Sohag University. The principal investigator is Esam M Abualfadl, Professor at Sohag University. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology